Monitor for a prospectus supplement or 424B filing indicating the terms of an offering. Given the dual shelf effectiveness and small market cap, an at-the-market (ATM) offering or direct placement is likely imminent. Short-term price pressure from dilution risk is expected.
Price Chart
Executive Summary
Can-Fite BioPharma received SEC effectiveness on two shelf registration statements (File Nos. 333-288890 and 333-269485) on September 11, 2026. This allows the company to sell securities at any time, creating a potential dilution overhang for the $5M market cap stock. The dual shelf effectiveness, combined with the company's small market cap and prior POS AM filings, suggests an imminent capital raise is likely.
Key Facts
- Two shelf registration statements (File Nos. 333-288890 and 333-269485) became effective on September 11, 2026.
- Can-Fite BioPharma has a market capitalization of approximately $5M.
- The company previously filed POS AM (post-effective amendments) for both shelf registrations, indicating active preparation for a securities offering.
- The shelf registrations allow the company to sell securities at any time, creating a persistent dilution overhang.
Financial Impact
Potential dilutive offering of undisclosed amount; at a $5M market cap, even a small raise could represent significant dilution.
Risk Factors
- Imminent dilutive equity offering could significantly reduce per-share value.
- Company's small market cap ($5M) means any raise is likely to be highly dilutive.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (CANF) — Batch item 1 | 9999999995-26-002945 |
| Document: 9999999995-26-002945-index.html | 9999999995-26-002944 |
| Document: 9999999995-26-002945.txt | 9999999995-26-002945 |
| EFFECT Filing (CANF) — Batch item 4 | 9999999995-26-002944 |
| Document: 9999999995-26-002944-index.html | 9999999995-26-002945 |
| Document: 9999999995-26-002944.txt | 9999999995-26-002945 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.95 | awaiting T+5 | — | $1.72 (−11.79%) |
Oct 13, 2026 13d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.72 (+11.79%) |
Oct 13, 2026 13d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.72 (+11.79%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.72 (+25.22%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.72 (−21.46%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.72 (−26.81%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.72 (−27.12%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.72 (+27.12%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.72 (−27.12%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.72 (−51.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers